fda warning letter glp-1 solution september 2025 Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s

FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

21.37

★★★★☆4.8 (126)

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

27.60

★★★★★4.9 (98)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

26.50

★★★★★5.0 (157)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

22.63

★★★★★4.7 (84)

FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling

25.26

★★★★★4.9 (203)

The FDA sent a warning letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know

27.36

★★★★★5.0 (176)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

29.24

★★★★★4.8 (132)